Compugen
Compugen's revenue rose 161.1% to $73 million in fiscal 2025. Its operating margin was 43.0%, up from −53.4% a year earlier. Free cash flow was $31 million, down 36.7%. The diluted share count rose 4.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Compugen does
Compugen is an Israeli drug developer working on cancer immunotherapy: medicines that help the body's immune system attack tumors. It uses its computer platform, called Unigen, to find new drug targets, and then develops antibodies against them. It has no approved products. Its programs are being tested in people, and the only trial it runs itself tests COM701 in women whose ovarian cancer has come back.
It makes money by licensing its targets and drug candidates to larger drug companies, in exchange for upfront fees, milestone payments and royalties. It has two such deals in effect. AstraZeneca is testing rilvegostomig, an antibody built from part of Compugen's COM902 program, in several trials, including late-stage ones. Gilead licensed GS-0321, which Compugen is testing in an early trial. Under the Gilead deal, Compugen can receive up to approximately $758 million more in milestone payments, plus royalties on sales.
Compugen recognized revenue of approximately $72.8 million from its partnerships in 2025, and it made a net profit of approximately $35.3 million that year after losses in earlier years. In 2025 it received $65 million as an additional upfront payment from AstraZeneca. After setbacks for other companies' drugs aimed at the same target, it does not plan new trials of COM902 on its own.
Its biggest risks, as it describes them
- It has a history of losses and may need to raise more money, which could dilute shareholders.
- It depends on a few drug candidates and on partners such as AstraZeneca and Gilead to develop and sell them.
- Clinical trials, its own or those of other companies testing the same targets, may fail to show the drugs are safe and work.
- Its computer-based way of finding drug targets is not yet proven in the clinic.
- Conditions in Israel and the Middle East could disrupt its operations.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 117 | 11 | 26 | 42 | 100 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −1,403.0x | −1,310.2x | −419.1x | −438.0x | 1,118.8x |
| Current ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
| Quick ratio | 7.2x | 7.2x | 4.4x | 5.3x | 6.6x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 238.3% | 160.9% | 204.2% |
| Altman Z'' | −7.46 | −8.87 | −0.84 |
| Accruals ratio | 15.9% | −54.0% | 2.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Compugen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Compugen | FY25 | 161.1% | 43.0% | 43.0% | — | — | — | |
| Cellectis | FY25 | 75.8% | −45.3% | −57.2% | — | — | — | Compare |
| Bicycle Therapeutics | FY25 | 105.8% | −340.4% | −347.2% | — | — | — | Compare |
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1 | — | 18 | — | 2 | 6 | 8 | 34 | 28 | 73 |
| Revenue growth | −92.3% | — | — | — | — | 200.0% | 25.0% | 346.1% | −16.7% | 161.1% |
| Gross profit | 0 | — | 17 | — | 2 | 5 | 6 | 32 | 20 | 64 |
| Research and development | 24 | 29 | 30 | 20 | 23 | 29 | 31 | 34 | 25 | 23 |
| Operating income | −33 | −37 | −23 | −29 | −32 | −35 | −35 | −13 | −15 | 31 |
| Net income | −32 | −37 | −23 | −27 | −30 | −34 | −34 | −19 | −14 | 35 |
| Diluted EPS (US$) | −0.62 | −0.72 | −0.41 | −0.43 | −0.37 | −0.41 | −0.39 | −0.21 | −0.16 | 0.38 |
| Diluted shares (millions) | 51 | 51 | 55 | 64 | 80 | 84 | 87 | 88 | 90 | 94 |
| Cash flow | ||||||||||
| Cash from operations | −20 | −31 | −13 | −28 | −28 | −23 | −34 | −36 | 50 | 32 |
| Capital expenditure | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −22 | −31 | −13 | −28 | −28 | −23 | −35 | −36 | 49 | 31 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 3 | 2 | 2 | 3 | 4 | 4 | 4 | 3 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 60 | 29 | 45 | 43 | 124 | 117 | 11 | 26 | 42 | 100 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 71 | 39 | 53 | 54 | 138 | 132 | 94 | 121 | 115 | 157 |
| Total liabilities | 8 | 9 | 16 | 15 | 18 | 26 | 16 | 56 | 60 | 54 |
| Shareholders' equity | 64 | 29 | 37 | 38 | 120 | 107 | 78 | 66 | 55 | 103 |
| Margins and ratios | ||||||||||
| Gross margin | 68.7% | — | 94.2% | — | 97.0% | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Operating margin | −4,576.3% | — | −130.5% | — | −1,574.8% | −584.6% | −471.6% | −38.8% | −53.4% | 43.0% |
| Net margin | −4,425.0% | — | −127.0% | — | −1,484.9% | −570.0% | −449.2% | −56.0% | −51.1% | 48.6% |
| Free cash flow margin | −3,148.6% | — | −75.6% | — | −1,424.3% | −383.1% | −461.2% | −107.8% | 177.6% | 43.0% |
| Rule of 40 (growth + FCF margin) | −3,240.9% | — | — | — | — | −183.1% | −436.2% | 238.3% | 160.9% | 204.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −41.1% | −79.9% | −67.9% | −72.3% | −37.6% | −30.2% | −36.5% | −26.2% | −23.6% | 44.8% |
| Return on assets | −37.0% | −67.5% | −49.2% | −51.1% | −30.9% | −25.3% | −29.8% | −17.4% | −12.0% | 26.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |